Menu
Deep Light Vision focuses on the development of a first product for molecular imaging in the field of cancer diagnostics, and subsequently for stroke and heart attack. The medical imaging market comprised $27 billion in 2020, and is expected to grow to $36 billion in 2027. The main part of the market comprises the traditional imaging technologies based on X-ray, magnetic resonance imaging, and ultrasound.
The mammography equipment market comprised $2.1 billion in 2022, with a sales volume of around 40,000 systems. Assuming that UOT systems in a first step can reach 5% of that volume, and a sales price of $250,000 per system, the market value for breast cancer diagnostics alone is $500 million.
Deep Light Vision has the vision to establish UOT as a general medical imaging method alongside the established ones, thereby opening a new market within the entire field of medical imaging.
Traditional imaging techniques such as X-ray, magnetic camera technology and ultrasound cannot image oxygenation in tissues and blood vessels in a simple way. Oxygenation is of vital importance for human survival and deficiencies in oxygenation are the cause of life-threatening acute conditions such as stroke and heart attack, which together constitute the cause of the majority of all deaths.
When a patient with a suspected stroke or heart attack comes into an emergency department, tests are done that can take up to an hour to carry out and analyze before the correct diagnosis can be made. With a UOT system in the emergency department, it could be possible to make a diagnosis within a few minutes after the patient enters. Valuable time can then be saved before the right treatment is initiated, which could improve the patient’s chances of survival and reduce the risk of permanent complications.
Ultrasound Optical Tomography (UOT) is a new and potentially ground-breaking technology in medical imaging alongside the traditional methods. In addition to cancer and emergency diagnostics, there are a number of possible applications of the technology for, for example, monitoring treatment response, diagnostics in non-acute conditions, and in sports medicine.
Our assessment is that the technology has the potential to revolutionize the market, and create a new use on a broad front within healthcare in a number of areas.
Two patent applications have been filed to protect the technology internationally. The patent applications cover technical solutions in a UOT system. The patent applications have been examined in the international phase (PCT) and will proceed for examination in the national phase in the countries and continents that represent the most important and largest markets.
The company intends to seek further patent protection for technical solutions that will be used in the research system that is now under development.
Deep Light Vision has been founded out of research at the Department of Physics at Lund University, by a research group led by Professor Stefan Kröll. The company management consists of Stefan Kröll, Johannes Swartling, who worked in companies such as SpectraCure, Gasporox, GPX Medical and NanoEcho, Tomas Kramar, former CEO of Siemens Healthineers Sweden, and Masoud Khayyami, well-known entrepreneur in life science companies.
DEEP LIGHT VISION AB
Gasverksgatan 3A
229 29 Lund Sweden
info@deeplightvision.com